Q-omics provides the consensus-scored NUTM2D profile across patient tissues and cancer cell-line models. NUTM2D expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NUTM2D is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, NUTM2D RNA expression shows 18,988 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, THCA, and THYM as cancer lineages where NUTM2D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTM2D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTM2D survival associations across molecular data types. NUTM2D RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTM2D RNA expression–survival associations across cancer types. High NUTM2D expression shows unfavorable associations in HNSC and BLCA, but favorable associations in UCS, LGG, KIRP and READ. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NUTM2D RNA expression.
This table summarizes NUTM2D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NUTM2D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTM2D shows lower tumor expression in THCA, KICH, COAD, KIRC and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher NUTM2D RNA expression in normal versus tumor tissue (log2 FC = −0.485, t-test p < 0.001).
This table shows molecular features associated with NUTM2D in patient tissues and cancer cell lines. In patient samples, NUTM2D shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUTM2D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
